Pyramid 2 + Type II BVD LPHThis page contains information on Pyramid 2 + Type II BVD LPH for veterinary use.
The information provided typically includes the following:
- Pyramid 2 + Type II BVD LPH Indications
- Warnings and cautions for Pyramid 2 + Type II BVD LPH
- Direction and dosage information for Pyramid 2 + Type II BVD LPH
Pyramid 2 + Type II BVD LPHThis treatment applies to the following species:
Bovine Rhinotracheitis-Virus Diarrhea Vaccine
Modified Live Virus
Leptospira Hardjo-Pomona Bacterin
For the vaccination of healthy cattle as an aid in the prevention of disease caused by bovine virus diarrhea (Types I and II), L. hardjo and L. pomona; and as an aid in the reduction of disease caused by bovine rhinotracheitis virus. This product aids in the prevention of persistent BVD Type I and Type II infection of the fetal calf when it is used subcutaneously in the cow or heifer 30 to 60 days pre-breeding. This vaccine may be used in pregnant cows or calves nursing pregnant cows provided the cows were vaccinated pre-breeding, according to label instructions, with Pyramid 5, Pyramid 10, or Pyramid 2 + Type II BVD (see inside carton for details). This product contains BVD Types I and II.
Summary Of Pregnant Cow Safety Study
Safety in pregnant cows and heifers was demonstrated in trials conducted in three separate herds of more than 1,400 cows. Prior to breeding, all animals were vaccinated with Pyramid® 5, a modified-live virus (MLV) vaccine containing IBR, BVD Type I & II, PI3 and BRSV. During the first, second or third trimester of pregnancy, the animals were vaccinated again. The pregnant cows received either Pyramid 5 or a killed virus (KV) IBR, BVD Type I & II, PI3 and BRSV vaccine (Triangle® 4 + Type II BVD). From pregnancy vaccination through calving, the cows were observed for fetal loss. Fetal loss in both groups was similar with 0.9% in the Pyramid 5 vaccinated groups and 1.6% in the KV vaccinated groups. In addition, no abortions due to IBR or BVD were identified in either group. Following birth, each calf’s health was monitored for 30 days. The health of calves born to Pyramid 5 vaccinated dams was similar to the health of calves born to the KV vaccinated dams. Fetal health risks associated with vaccination of pregnant animals with modified-live vaccines cannot be unequivocally determined by clinical trials conducted for Iicensure. Vaccination of pregnant animals with modified-live vaccines should be discussed with a veterinarian.
DOSE: Aseptically rehydrate with the accompanying diluent. Cattle, inject one 2 mL dose subcutaneously or intramuscularly using aseptic technique. Annual revaccination is recommended. Protect animals from exposure for at least 14 days after vaccination. Calves vaccinated under six months of age should be revaccinated at six months of age.
Pyramid 2 + Type II BVD LPH Caution
Store in the dark at 2° to 7°C (35° to 45°F). AVOID FREEZING. SHAKE WELL. Use entire contents when first opened. A small percentage of animals may show transient mild injection site swelling. Do not vaccinate within 21 days before slaughter. Burn container and all unused contents. In case of anaphylactoid reaction, administer epinephrine.
Thimerosal, neomycin and polymyxin B added as preservatives.
For Veterinary Use Only
© 2007 Fort Dodge Animal Health. All Rights Reserved.
Fort Dodge Animal Health, Fort Dodge, Iowa 50501 USA
U.S. Vet. License No. 112
One vial vaccine, One vial diluent
50 Doses - Rehydrate to 100 mL
NAC No.: 10282590
2621 NORTH BELT HIGHWAY, ST. JOSEPH, MO, 64506-2002
|Every effort has been made to ensure the accuracy of the Pyramid 2 + Type II BVD LPH information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2016 North American Compendiums. Updated: 2016-10-31